Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGE 98: mFOLFIRINOX in Resected Ampullary Adenocarcinoma
NCT06813976Phase 3Recruiting
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Jul 2025
- Primary completion
- Jul 2033
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, irinotecan and fluorouracil in ampullary adenocarcinoma (2 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Disease-free survival at 36 months. Started Jul 2025; status: recruiting.
02
Drugs
oxaliplatinirinotecanfluorouracil
03
Conditions
ampullary adenocarcinoma
Beyond the preview
Go deeper on NCT06813976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06813976.